What Should The Chemours Company Investors Know After 18.63% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

Lawsuit alleges The Chemours Company made misleading statements to investors from February 20, 2026 to August 4, 2026; lead plaintiff motions are due December 7, 2026

LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors who acquired the Company's securities from February 20, 2026 to August 4, 2026. Filed on October 8, 2026, the case is Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington), Case No. 1:26-cv-01299.

If you lost money on The Chemours Company securities, submit your The Chemours Company loss information by December 7, 2026 to learn about participating in the lawsuit.

The Chemours Company class action timeline

• Class period begins: February 20, 2026
• Class period ends: August 4, 2026
• Complaint filed: October 8, 2026
• Lead plaintiff motion deadline: December 7, 2026

What happened?

On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."

On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.

What is the Chemours Company lawsuit about?

The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

"According to the complaint filed against The Chemours Company, the Company, among other things, did not disclose that Defendants had materially overstated aftermarket demand for their Opteon products. The December 7, 2026 deadline is a key date for The Chemours Company investors who want a voice in how this case moves forward," said Frank R. Cruz of The Law Offices of Frank R. Cruz.

What should The Chemours Company investors do now?

The Law Offices of Frank R. Cruz can help The Chemours Company investors evaluate potential claims to recover their losses.

Investors who want to serve as lead plaintiff in the Chemours Company class action must file a motion with the Court by December 7, 2026. For more information, visit the Chemours Company case page, email [email protected], or call 310-914-5007.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

Investors may retain counsel of their choice. The Chemours Company investors who bought during the class period may also take no action and remain absent class members. No class has been certified yet in the Chemours Company case.

Questions and answers about the Chemours Company lawsuit

Who is eligible? Investors who bought The Chemours Company securities between February 20, 2026 and August 4, 2026 and lost money may be class members, and may seek lead plaintiff appointment by December 7, 2026.

What does a lead plaintiff do? The lead plaintiff is appointed by the court to represent all class members and direct the Chemours Company class action.

Must I be lead plaintiff to share in a recovery? No, The Chemours Company investors can take no action and remain absent class members.

How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval.

About The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.

Prior results do not guarantee a similar outcome.

Related links

• The Chemours Company case page, The Law Offices of Frank R. Cruz
• Complaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington)
• press release
• The Chemours Company SEC filings index, EDGAR
• The Law Offices of Frank R. Cruz

Follow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE The Law Offices of Frank R. Cruz, Los Angeles